The majority of our revenues come from the manufacture and sale of biopharmaceutical products. All rights reserved.
The operating results of this business are reported as Income from discontinued operations——net of tax in our consolidated statements of income through August 1,the date of disposal.
Securities and Exchange Commission and available at www. This webcast may contain forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, the benefits expected from the reorganization of our commercial operations into three businesses effective at the beginning of our fiscal year, our acquisitions and other business development activities, our proposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture, our ability to successfully capitalize on growth opportunities or prospects, manufacturing and product supply and plans relating to share repurchases and dividends, among other things, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
Hospira is now a subsidiary of Pfizer and its commercial operations are now included within the Global Established Pharmaceutical GEP segment. The forward-looking statements in the webcast speak only as of the original date of the webcast.
Pending Combination with Allergan for additional information. These factors include, among others: the loss or expiration of intellectual property rights and the expiration of co-promotion and licensing rights, healthcare legislation, pipeline productivity, the regulatory environment, pricing and access pressures and competition.
The assets, liabilities, operating results and cash flows of acquired businesses, such as King Pharmaceuticals, Inc.